No matches
Dermatology

ADVENT On-Air Podcast: Growth and Children With AD

Drs. Amy Paller and Lisa Swanson discuss the risk of low bone mineral density and impaired growth reported in pediatric atopic dermatitis and observed improvements in growth with advanced therapy, especially among children of shorter stature at baseline.
Amy Paller
Lisa Swanson
MD, MS
Amy Paller +1 more

Related resources

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

Infographic
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Explore the Global Burden of Pediatric AD (PEDISTAD)

Explore the Global Burden of Pediatric AD (PEDISTAD)

interactivity
Type 2 Inflammation Within Skin Tissue in AD

Type 2 Inflammation Within Skin Tissue in AD

expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

expert video
Diving Below the Surface of AD: The Role of Type 2 Inflammation

Diving Below the Surface of AD: The Role of Type 2 Inflammation

expert video
Considerations for Disease Modification in AD

Considerations for Disease Modification in AD

expert video
The Role of Type 2 Inflammation in Moderate-to-Severe AD

The Role of Type 2 Inflammation in Moderate-to-Severe AD

expert video
Identification and Management of AD Uncontrolled With Topical Therapies in Children

Identification and Management of AD Uncontrolled With Topical Therapies in Children

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
Atopic Dermatitis in Children: Not Just a Skin Disease

Atopic Dermatitis in Children: Not Just a Skin Disease

expert video
Type 2 Inflammation and Its Role in Atopic Dermatitis

Type 2 Inflammation and Its Role in Atopic Dermatitis

expert video
Persistence of AD From Childhood Into Adulthood

Persistence of AD From Childhood Into Adulthood

expert video
Key Treatment Considerations for Management of Atopic Dermatitis in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

expert video
Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

expert video
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

expert video
Early Intervention and the Potential For Disease Modification in AD

Early Intervention and the Potential For Disease Modification in AD

expert video
Emerging Real-World Data on Advanced Systemic Therapies in AD

Emerging Real-World Data on Advanced Systemic Therapies in AD

expert video
Real-World Effectiveness of Advanced Systemic Treatments in AD

Real-World Effectiveness of Advanced Systemic Treatments in AD

expert video
The Importance of Early Intervention and the Potential for Disease Modification in Patients With AD

The Importance of Early Intervention and the Potential for Disease Modification in Patients With AD

expert video
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
Chronic Spontaneous Urticaria Mechanism of Disease Animation

Chronic Spontaneous Urticaria Mechanism of Disease Animation

videoanimation
CSU Burden Related to Chronicity and Patient Journey

CSU Burden Related to Chronicity and Patient Journey

expert video
The Clinical Presentation of CSU is Heterogeneous

The Clinical Presentation of CSU is Heterogeneous

expert video
The Role of Type 2 Inflammation in Multiple Disease Trajectories

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Infographic
Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

Podcast
Latest Real-World Data on Advanced Systemic Treatments for Patients With AD

Latest Real-World Data on Advanced Systemic Treatments for Patients With AD

expert video
The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)

Infographic
The Importance of Disease Control in Reducing CSU Patient Burden

The Importance of Disease Control in Reducing CSU Patient Burden

expert video
Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
KOL Video Interview – Dr. Eric Simpson

KOL Video Interview – Dr. Eric Simpson

expert video
Emerging Therapeutics: Addressing the Gaps in CSU Patient Care

Emerging Therapeutics: Addressing the Gaps in CSU Patient Care

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
KOL Video Interview – Dr Amy Paller

KOL Video Interview – Dr Amy Paller

expert video
KOL Video Interview – Dr Paula Luna

KOL Video Interview – Dr Paula Luna

expert video
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

expert video
The Chronic Nature of CSU: Understanding Disease Duration and Persistence

The Chronic Nature of CSU: Understanding Disease Duration and Persistence

expert video
The Role of IL-4 and IL-13 in the Pathophysiology of CSU

The Role of IL-4 and IL-13 in the Pathophysiology of CSU

expert video

Learning objectives

  • Explore the correlation between moderate-to-severe AD and vertical growth in pediatric patients
  • Discuss the potential pathomechanisms of AD that may contribute to suboptimal bone mineralization and growth impairment
  • Describe the improvements in growth observed in pediatric patients with moderate-to-severe AD who received dupilumab treatment
Tags
type 2 inflammationAtopic DermatitispediatricVertical Growthbiomarkers
MAT-GLB-2604085 - 1.0 - 07/2026

About these experts

Dermatology
MD, MS

Amy Paller

Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US

Dermatology
MD

Lisa Swanson

Dermatologist and Pediatric Dermatologist at Ada West Dermatology | Boise, Idaho, United States

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United Arab EmiratesChange country/region